Food and Drug Administration Amendments Act of 2007
E167140
The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
All labels observed (4)
How this entity was disambiguated
This entity first appeared as the object of triple T1445201 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
Target entity: Food and Drug Administration Amendments Act of 2007 Context triple: [Federal Food, Drug, and Cosmetic Act, amendedBy, Food and Drug Administration Amendments Act of 2007]
-
A.
Food and Drug Administration Modernization Act of 1997
The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
-
B.
Drug Price Competition and Patent Term Restoration Act of 1984
The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
-
C.
Kefauver–Harris Drug Amendments of 1962
The Kefauver–Harris Drug Amendments of 1962 are U.S. federal regulations that strengthened drug safety and efficacy requirements, mandating proof of effectiveness and stricter oversight of pharmaceutical marketing and manufacturing.
-
D.
Federal Food, Drug, and Cosmetic Act
The Federal Food, Drug, and Cosmetic Act is a key U.S. law that authorizes the Food and Drug Administration to regulate the safety, labeling, and marketing of food, drugs, medical devices, and cosmetics.
-
E.
Ryan Haight Online Pharmacy Consumer Protection Act of 2008
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 is a U.S. federal law that regulates internet pharmacies by requiring valid prescriptions and in-person medical evaluations before dispensing controlled substances online.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Target entity: Food and Drug Administration Amendments Act of 2007 Target entity description: The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
-
A.
Food and Drug Administration Modernization Act of 1997
The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
-
B.
Drug Price Competition and Patent Term Restoration Act of 1984
The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
-
C.
Kefauver–Harris Drug Amendments of 1962
The Kefauver–Harris Drug Amendments of 1962 are U.S. federal regulations that strengthened drug safety and efficacy requirements, mandating proof of effectiveness and stricter oversight of pharmaceutical marketing and manufacturing.
-
D.
Federal Food, Drug, and Cosmetic Act
The Federal Food, Drug, and Cosmetic Act is a key U.S. law that authorizes the Food and Drug Administration to regulate the safety, labeling, and marketing of food, drugs, medical devices, and cosmetics.
-
E.
Ryan Haight Online Pharmacy Consumer Protection Act of 2008
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 is a U.S. federal law that regulates internet pharmacies by requiring valid prescriptions and in-person medical evaluations before dispensing controlled substances online.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
United States federal statute
ⓘ
health law ⓘ |
| abbreviation | FDAAA ⓘ |
| aimsTo |
enhance FDA resources through user fees
ⓘ
improve device safety monitoring ⓘ improve drug safety monitoring ⓘ increase transparency of clinical research ⓘ strengthen post-market surveillance ⓘ |
| amends | Federal Food, Drug, and Cosmetic Act ⓘ |
| containsProvision |
active risk communication to healthcare professionals
ⓘ
drug labeling safety updates ⓘ pediatric research incentives ⓘ post-market risk identification and analysis system ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| creates |
FDA Risk Evaluation and Mitigation Strategies authority
ⓘ
FDA authority to mandate clinical trial registration ⓘ FDA authority to mandate clinical trial results reporting ⓘ FDA authority to require post-marketing clinical trials ⓘ FDA authority to require post-marketing studies ⓘ FDA authority to require safety-related labeling changes ⓘ FDA authority to restrict distribution of certain drugs ⓘ |
| effectiveIn |
United States of America
ⓘ
surface form:
United States
|
| enactedBy | 110th United States Congress ⓘ |
| establishes | ClinicalTrials.gov results reporting requirements ⓘ |
| establishesProgram |
Food and Drug Administration Safety and Innovation Act of 2012
ⓘ
surface form:
Medical Device User Fee and Modernization Act reauthorization
Prescription Drug User Fee Act of 1992 ⓘ
surface form:
Prescription Drug User Fee Act reauthorization
pediatric drug user fee program ⓘ |
| expandsAuthorityOf |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| hasSection |
Food and Drug Administration Amendments Act of 2007
self-linksurface differs
ⓘ
surface form:
Title II—Medical Device User Fee Amendments of 2007
Food and Drug Administration Amendments Act of 2007 self-linksurface differs ⓘ
surface form:
Title I—Prescription Drug User Fee Amendments of 2007
Title VIII—Clinical Trial Databases ⓘ |
| legalDomain |
food and drug law
ⓘ
public health law ⓘ |
| primaryAgencyAffected |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| publicLawNumber | Public Law 110-85 ⓘ |
| regulates |
biological products
ⓘ
clinical trials of drugs and devices ⓘ medical devices ⓘ prescription drugs ⓘ |
| shortName |
Food and Drug Administration Amendments Act of 2007
self-linksurface differs
ⓘ
surface form:
FDA Amendments Act of 2007
|
| signedBy | George W. Bush ⓘ |
| signingDate | 2007-09-27 ⓘ |
| subjectOf |
clinical trial transparency
ⓘ
device safety ⓘ drug safety ⓘ post-market surveillance ⓘ |
| title | An Act to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish a user-fee program for pediatric drugs, and for other purposes ⓘ |
| yearEnacted | 2007 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Subject: Food and Drug Administration Amendments Act of 2007 Description of subject: The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.